Posted on

Cheetah Net Supply Chain Service Inc. Enters into Agreement to Acquire JoyPak Supply LLC

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Cheetah Net Supply Chain Service Inc. (“Cheetah” or the “Company”) (Nasdaq CM: CTNT) today announced that it has entered into a Membership Interest Purchase Agreement (the “Agreement”) to acquire 100% of the membership interests of JoyPak Supply LLC (“JoyPak”), a Nevada limited liability company, primarily engaged in the sale of consumer, beauty, personal care and other everyday-use products, from a Delaware limited liability company and a Texas limited liability company (collectively, the “Sellers”) (the “Acquisition”).

By sf-admin
Posted on

ZenaTech Closes 29th Drone as a Service Acquisition Adding Solar and Railroad Customers with Georgia-based U.S. Land Surveying Company Holding Licenses in 17 States

VANCOUVER, British Columbia, Sept. 15, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that it has completed the acquisition of Merritt Paul Land Surveying, LLC (Merritt Paul), a land surveying firm based in Franklin, Georgia. Founded in 2015, Merritt Paul has built a track record providing surveying services to the solar, transportation and construction industries, including work for a major national transportation company, and specializes in utility-scale solar surveys across the U.S. The company is licensed to preform land surveys in 17 states. The acquisition marks ZenaTech’s 29th Drone as a Service acquisition to date.

By sf-admin
Posted on

Rocket Lab Fully Funds Iridium Acquisition, Including Completion of $1.94 Billion ATM

LONG BEACH, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today announced it has successfully completed several critical milestones to fully finance its pending acquisition of Iridium Communications Inc. (“Iridium” and such pending transaction, the “Iridium Acquisition”).

By sf-admin
Posted on

Rocket Lab Fully Funds Iridium Acquisition, Including Completion of $1.94 Billion ATM

LONG BEACH, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or the “Company”), a global leader in launch services and space systems, today announced it has successfully completed several critical milestones to fully finance its pending acquisition of Iridium Communications Inc. (“Iridium” and such pending transaction, the “Iridium Acquisition”).

By sf-admin
Posted on

TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026

Basel, September 15, 2026 – TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company pioneering therapies targeting non-oncogene addiction in cancer, today announced the completion of its Phase I study of monotherapy TT125-802 (NCT06403436) and the presentation of final clinical data from the study at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. The data highlights TT125-802’s confirmed clinical activity as monotherapy in drug-resistant NSCLC and supports CBP/p300 inhibition as a novel therapeutic strategy to address transcriptional drug resistance in solid tumors.

By sf-admin
Posted on

TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026

Basel, September 15, 2026 – TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company pioneering therapies targeting non-oncogene addiction in cancer, today announced the completion of its Phase I study of monotherapy TT125-802 (NCT06403436) and the presentation of final clinical data from the study at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea. The data highlights TT125-802’s confirmed clinical activity as monotherapy in drug-resistant NSCLC and supports CBP/p300 inhibition as a novel therapeutic strategy to address transcriptional drug resistance in solid tumors.

By sf-admin
Posted on

Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program

VIENNA, September 15, 2026 — Aitiologic, a precision medicine company developing tissue-resolved liquid biopsy solutions, today announced the close of a significantly oversubscribed €6.4 million (approximately $7.4 million) seed financing, co-led by Heal Capital and Ananda Impact Ventures. The financing will support ongoing large-scale validation and regulated product development of Aitios®, the company’s multi-modal cell-free DNA (cfDNA) platform, initially for first-trimester preeclampsia risk stratification. Dr. Gordon Sanghera CBE FRS, an established pioneer in molecular diagnostics, participated in the seed round as an investor and will join the company’s advisory board. To further advance the clinical translation of the preeclampsia lead program, Dr. Rebecca Ertl has been appointed Chief Medical Officer.

By sf-admin